Edward Tenthoff
Stock Analyst at Piper Sandler
(2.23)
# 2,490
Out of 4,862 analysts
182
Total ratings
38.51%
Success rate
-2.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Assumes: Overweight | $7 | $2.36 | +196.61% | 1 | Jun 3, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $6 → $9 | $6.83 | +31.77% | 4 | May 29, 2025 | |
| ITOS iTeos Therapeutics | Maintains: Overweight | $16 → $12 | $10.18 | +17.88% | 1 | May 14, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | $24 → $14 | $7.39 | +89.45% | 7 | May 2, 2025 | |
| IPSC Century Therapeutics | Maintains: Overweight | $4 → $2 | $0.58 | +247.58% | 8 | Mar 20, 2025 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $53 → $48 | $14.40 | +233.33% | 6 | Feb 28, 2025 | |
| MESO Mesoblast | Reiterates: Overweight | $15 → $24 | $11.78 | +103.74% | 5 | Feb 7, 2025 | |
| LEGN Legend Biotech | Reiterates: Overweight | $78 | $36.83 | +111.78% | 4 | Dec 30, 2024 | |
| XNCR Xencor | Upgrades: Overweight | $20 → $30 | $9.16 | +227.51% | 4 | Dec 2, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | $62 → $45 | $15.74 | +185.90% | 11 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $296 | $307.99 | -3.89% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $115 → $69 | $26.67 | +158.72% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $6 → $1 | $0.89 | +12.03% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $6.61 | +883.36% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $1.55 | +1,061.29% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $11.78 | +197.11% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $0.80 | +1,276.55% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $2.05 | +875.61% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.33 | +125.56% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.59 | +408.47% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $4.91 | +225.87% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $41.36 | +153.87% | 6 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.28 | +370.59% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.65 | +203.03% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $46.96 | +19.25% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $31 | $1.04 | +2,880.77% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $2.82 | +3,091.49% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $6 | $0.68 | +781.06% | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $7.50 | +2,300.00% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $19.50 | +125.64% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $8.36 | +342.58% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2,246,640 → $651,200 | $4.39 | +14,833,612.98% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $577.89 | -38.74% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.25 | +10,722.51% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $455.45 | -29.08% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $41.59 | -13.44% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.60 | +1,462.50% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.84 | +17,757.14% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $53 | $1.21 | +4,280.17% | 2 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $0.67 | +204,405.04% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $529.24 | - | 11 | Feb 13, 2017 |
Biomea Fusion
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $2.36
Upside: +196.61%
Fulcrum Therapeutics
May 29, 2025
Maintains: Overweight
Price Target: $6 → $9
Current: $6.83
Upside: +31.77%
iTeos Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $10.18
Upside: +17.88%
Arvinas
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $7.39
Upside: +89.45%
Century Therapeutics
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.58
Upside: +247.58%
Dyne Therapeutics
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $14.40
Upside: +233.33%
Mesoblast
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $11.78
Upside: +103.74%
Legend Biotech
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $36.83
Upside: +111.78%
Xencor
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $9.16
Upside: +227.51%
Arrowhead Pharmaceuticals
Nov 27, 2024
Maintains: Overweight
Price Target: $62 → $45
Current: $15.74
Upside: +185.90%
Nov 18, 2024
Reiterates: Overweight
Price Target: $296
Current: $307.99
Upside: -3.89%
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $26.67
Upside: +158.72%
Nov 14, 2024
Downgrades: Neutral
Price Target: $6 → $1
Current: $0.89
Upside: +12.03%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $6.61
Upside: +883.36%
Nov 5, 2024
Initiates: Overweight
Price Target: $18
Current: $1.55
Upside: +1,061.29%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $11.78
Upside: +197.11%
Oct 11, 2024
Reiterates: Overweight
Price Target: $11
Current: $0.80
Upside: +1,276.55%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $2.05
Upside: +875.61%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.33
Upside: +125.56%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.59
Upside: +408.47%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $4.91
Upside: +225.87%
Jun 17, 2024
Reiterates: Overweight
Price Target: $105
Current: $41.36
Upside: +153.87%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.28
Upside: +370.59%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.65
Upside: +203.03%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $46.96
Upside: +19.25%
Aug 14, 2023
Maintains: Overweight
Price Target: $28 → $31
Current: $1.04
Upside: +2,880.77%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $2.82
Upside: +3,091.49%
Nov 4, 2022
Maintains: Overweight
Price Target: $13 → $6
Current: $0.68
Upside: +781.06%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $7.50
Upside: +2,300.00%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $19.50
Upside: +125.64%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $8.36
Upside: +342.58%
May 13, 2022
Maintains: Overweight
Price Target: $2,246,640 → $651,200
Current: $4.39
Upside: +14,833,612.98%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $577.89
Upside: -38.74%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.25
Upside: +10,722.51%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $455.45
Upside: -29.08%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $41.59
Upside: -13.44%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.60
Upside: +1,462.50%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.84
Upside: +17,757.14%
Jan 6, 2020
Maintains: Overweight
Price Target: $26 → $53
Current: $1.21
Upside: +4,280.17%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $0.67
Upside: +204,405.04%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $529.24
Upside: -